- July 03, 2018
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Completes New Production Facility for Highly Potent Pharmaceutical Ingredients at Saitama Site
Company Aims to Speed up New Drug Development
Taiho Pharmaceutical Co., Ltd. announced today that it has completed construction of a new production facility, called the HP building, for highly potent pharmaceutical ingredients at its Saitama Site on July 2, 2018.
The HP building is capable of producing many kinds of substances, including the production of highly potent pharmaceutical ingredients for molecular targeted drugs, focusing on anticancer drugs. It was designed to respond to production needs for investigational drug substances and initial commercialization. This will enable Taiho Pharmaceutical to flexibly and rapidly respond to development plans for new drug candidate compounds discovered in house. The company will leverage the facility to further advance its global development of new drugs. As a facility capable of producing highly potent pharmaceutical ingredients, the HP building uses different containment technology from that of a manufacturing facility for general active pharmaceutical ingredients, in order to ensure the safety of employees and the surrounding area.
With the construction of the HP building, Taiho Pharmaceutical will speed up new drug development in an effort to promptly deliver innovative new drugs to patients and medical professionals.
Overview of the HP building
| Location | 200-22, Motohara, Kamikawa Machi, Kodama Gun, Saitama Prefecture, Japan |
|---|---|
| Floor area | Around 4,700m2 |
| Building structure | Three-story steel construction |
| Completed | July 2, 2018 |
| Estimated operations commencement date | October 2018 |
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.